Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation

Thiago Moreno L. Souza(National Institute of Science and Technology), Jaime A. Rabi(Department of Physiological Sciences)
Nature Communications
January 13, 2023
Cited by 15


Related Papers